Repligen Corporation Dividend History (RGEN)
Repligen Corporation does not pay dividends currently 😔
They might in the future, check back soon!
About Repligen Corporation
Repligen Corporation is a life sciences company that specializes in the development and production of bioprocessing products used in the manufacturing of biologic drugs. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen is a key player within the biopharmaceutical industry, offering innovative products and solutions that enhance the processes of drug manufacturing. As of 2023, the CEO of Repligen is Tony J. Hunt, who has been instrumental in the company's growth and expansion. The company has seen significant revenue growth over the years, driven by its focus on technologies such as filtration and chromatography, which are critical in biologics development. Repligen is well-regarded for its customer-centric approach and commitment to quality, supporting clients in expediting the development and market reach of life-saving therapeutics.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Thermo Fisher Scientific Inc.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Justin Bowers upgraded the rating for Repligen Corporation (NASDAQ:RGEN) from Hold to Buy, but lowered the price target from $180 to $155. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock. Wolfe Research analyst Steven Chubak ...
Benzinga · Published on Wed Jun 26 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, In...
Benzinga · Published on Wed Jun 26 2024
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research · Published on Mon Jun 24 2024